Thailand’s first batch of the royal-gifted cancer medicine Imcranib 100 has been delivered to the Government Pharmaceutical Organisation (GPO), paving the way for distribution to hospitals nationwide. The move is expected to improve access to modern targeted cancer treatment for patients covered under Thailand’s Universal Coverage Scheme.
Get today's headlines by email 
Deputy Government Spokesperson Ploythalee Laksamisaengchan announced on 4 June 2026 that Professor Dr Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana had donated 690,000 tablets of Imcranib 100 to the National Health Security Office (NHSO). The donation was made to mark her birthday on 4 July 2026 under the “69th Birthday Anniversary Cancer Medicine Project”.
According to the government, the first production batch for the NHSO was completed and delivered on 2 June 2026 by the Pharmaceutical Manufacturing Facility under the Royal Initiative of the Chulabhorn Royal Academy. The medicines were transferred to the GPO distribution centre, which serves as the NHSO’s primary medicine distribution hub.
All warehousing and transport processes are being carried out under Good Distribution Practice (GDP) standards. Officials said the procedures are designed to maintain the quality, safety and effectiveness of the medicine until it reaches patients.
Imcranib 100 is a targeted cancer treatment in tablet form. Targeted therapies work by focusing on specific molecular or genetic features that help cancer cells grow and spread, allowing treatment to be directed at cancer cells while limiting effects on healthy tissue.
Imcranib 100 was developed and manufactured in Thailand by the Chulabhorn Royal Academy. The drug was developed at the Royal Initiative Pharmaceutical Plant in Chon Buri Province, specifically at a pharmaceutical manufacturing facility established under the initiative of Princess Chulabhorn Krom Phra Srisavangavadhana.
The government described Imcranib 100 as a modern cancer medicine intended to improve access to advanced treatment for eligible patients. The donation forms part of wider efforts to expand access to innovative medicines through Thailand’s public healthcare system. By providing the medicine through the NHSO, eligible patients under the Universal Coverage Scheme will be able to receive treatment through participating healthcare facilities across the country.
The GPO will now take responsibility for distributing Imcranib 100 to healthcare units and hospitals nationwide in accordance with the NHSO’s distribution plan. The aim is to ensure patients have equitable access to the treatment regardless of where they live.
Komchadluek reported that the delivery of the first batch marks the beginning of the nationwide rollout. Further distribution to hospitals is expected to follow as the medicine is allocated through the public health network to reach eligible patients throughout Thailand.
Pictures courtesy of Komchadluek
Join the discussion? 
Already a member? 
Adapted by ASEAN Now Komchadluek 5 June 2026
-
1